ReviewCardiac failure review2018
Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure.
Review in Cardiac failure review, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Sympathetic and hemodynamic responses to exercise in heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2023Review
- Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?Journal of clinical medicine · 2022Review
- Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?European journal of heart failure · 2022Review
- Prioritizing symptom management in the treatment of chronic heart failure.ESC heart failure · 2020Review
- Monitoring of iron status in patients with heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Care plans for the older heart failure patient.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Frailty in patients with heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Clinical case: heart failure and ischaemic heart disease.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.